QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
Log in
NASDAQ:STSA

Satsuma Pharmaceuticals Stock Forecast, Price & News

$4.33
0.00 (0.00 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.28
Now: $4.33
$4.55
50-Day Range
$4.33
MA: $18.80
$25.63
52-Week Range
$4.15
Now: $4.33
$36.10
Volume1.16 million shs
Average Volume813,235 shs
Market Capitalization$75.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.
Read More
Satsuma Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryRegional Banks
SectorMedical
Current SymbolNASDAQ:STSA
CUSIP85931930
Phone650-410-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.64 per share

Profitability

Net Income$-28,170,000.00

Miscellaneous

Employees11
Market Cap$75.38 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$4.33
0.00 (0.00 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STSA News and Ratings via Email

Sign-up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

How has Satsuma Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Satsuma Pharmaceuticals' stock was trading at $23.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STSA stock has decreased by 81.8% and is now trading at $4.33.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Satsuma Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Satsuma Pharmaceuticals
.

When is Satsuma Pharmaceuticals' next earnings date?

Satsuma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Satsuma Pharmaceuticals
.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals (NASDAQ:STSA) announced its quarterly earnings results on Wednesday, August, 12th. The financial services provider reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.07.
View Satsuma Pharmaceuticals' earnings history
.

What price target have analysts set for STSA?

4 brokers have issued 1-year price targets for Satsuma Pharmaceuticals' shares. Their forecasts range from $4.00 to $7.00. On average, they expect Satsuma Pharmaceuticals' stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price.
View analysts' price targets for Satsuma Pharmaceuticals
.

Are investors shorting Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 280,700 shares, an increase of 12.6% from the August 15th total of 249,300 shares. Based on an average daily volume of 1,810,000 shares, the short-interest ratio is currently 0.2 days. Currently, 2.2% of the company's stock are sold short.
View Satsuma Pharmaceuticals' Short Interest
.

Who are some of Satsuma Pharmaceuticals' key competitors?

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE), Verrica Pharmaceuticals (VRCA), Applied Therapeutics (APLT) and Algonquin Power & Utilities (AQN).

Who are Satsuma Pharmaceuticals' key executives?

Satsuma Pharmaceuticals' management team includes the following people:
  • Mr. John A. Kollins, Pres, CEO & Director (Age 56)
  • Dr. Detlef F. Albrecht, Chief Medical Officer (Age 58)
  • Mr. Thomas P. O'Neil, Chief Financial Officer (Age 54)
  • Mr. Mic Iwashima, VP & Head of Operations (Age 41)
  • Mr. Robert Schultz, VP & Head of CMC (Age 55)

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Who are Satsuma Pharmaceuticals' major shareholders?

Satsuma Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (4.59%), Ikarian Capital LLC (1.89%), Point72 Asset Management L.P. (0.36%), Charles Schwab Investment Management Inc. (0.26%), Nuveen Asset Management LLC (0.21%) and Goldman Sachs Group Inc. (0.17%). Company insiders that own Satsuma Pharmaceuticals stock include Detlef Albrecht, Group Holdings (Sbs) Advis Tpg, Louis F Centofanti, Rajeev M Shah and Thomas P O'neil.
View institutional ownership trends for Satsuma Pharmaceuticals
.

Which major investors are selling Satsuma Pharmaceuticals stock?

STSA stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP. Company insiders that have sold Satsuma Pharmaceuticals company stock in the last year include Detlef Albrecht, and Thomas P O'neil.
View insider buying and selling activity for Satsuma Pharmaceuticals
.

Which major investors are buying Satsuma Pharmaceuticals stock?

STSA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., Nuveen Asset Management LLC, California Public Employees Retirement System, Charles Schwab Investment Management Inc., Quantitative Systematic Strategies LLC, and Bank of New York Mellon Corp. Company insiders that have bought Satsuma Pharmaceuticals stock in the last two years include Group Holdings (Sbs) Advis Tpg, Louis F Centofanti, and Rajeev M Shah.
View insider buying and selling activity for Satsuma Pharmaceuticals
.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $4.33.

How big of a company is Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals has a market capitalization of $75.38 million. The financial services provider earns $-28,170,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Satsuma Pharmaceuticals employs 11 workers across the globe.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is www.satsumarx.com.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.